What Myriad Genetics Does

Myriad Genetics is a leading precision medicine company founded in 1991, specializing in hereditary cancer risk assessment and genetic testing. Based in Salt Lake City, Utah, the company analyzes an individual's DNA to identify mutations associated with increased risks for cancers such as breast, ovarian, colorectal, and melanoma. Its flagship products include tests like myRisk® Hereditary Cancer, which assesses multiple genes simultaneously. By providing clinicians with actionable genetic information, Myriad empowers personalized healthcare decisions, from enhanced screening to preventive surgeries, for patients and their families.

Why AI Matters at This Scale

As a mid-to-large enterprise with over 1,000 employees and nearly $1B in revenue, Myriad operates at a scale where operational efficiency and innovation are critical for maintaining competitive advantage. The biotechnology sector, particularly genomics, is inherently data-intensive. Each test generates vast amounts of complex genomic data, and the manual interpretation of genetic variants—especially Variants of Uncertain Significance (VUS)—is a significant bottleneck. AI and machine learning offer the computational power to analyze these massive datasets, uncover subtle patterns, and automate labor-intensive processes. For a company like Myriad, this translates directly into faster turnaround times, improved test accuracy, reduced costs, and the ability to develop next-generation, more comprehensive risk models that can drive future growth.

Concrete AI Opportunities with ROI Framing

1. Automating Variant Interpretation: Deploying AI models to classify VUS can drastically reduce the time genetic counselors and scientists spend on manual review. A conservative estimate suggests automation could handle 30-40% of preliminary classifications, accelerating report generation by days. This improves patient satisfaction and allows highly skilled staff to focus on the most complex cases, enhancing both lab capacity and diagnostic quality. The ROI includes increased test throughput without proportional headcount growth. 2. Optimizing Laboratory Operations: Machine learning algorithms can predict daily test volumes, reagent consumption, and potential equipment failures. By moving from reactive to predictive maintenance and inventory management, Myriad can minimize costly instrument downtime and reduce waste. This operational intelligence could lead to a 5-10% reduction in direct lab operating costs, contributing significantly to margin improvement. 3. Enhancing Clinical Decision Support: Integrating AI that synthesizes genetic data with electronic health record information can generate personalized, evidence-based clinical management recommendations. This adds value to the test report, potentially justifying premium pricing and strengthening partnerships with healthcare providers. It also opens avenues for new service offerings, such as AI-powered clinical trial matching, creating new revenue streams.

Deployment Risks Specific to This Size Band

For a company of Myriad's size (1,001-5,000 employees), deploying AI introduces specific risks. Integration Complexity: Embedding AI into legacy laboratory information systems (LIS) and clinical reporting workflows is a major technical challenge that can disrupt operations if not managed carefully. Talent Scarcity: Competing with tech giants and startups for top AI and data science talent is difficult and expensive, potentially slowing project velocity. Regulatory Hurdles: Any AI used for diagnostic purposes must undergo rigorous validation for Clinical Laboratory Improvement Amendments (CLIA) compliance and possibly FDA review, a lengthy and costly process. Change Management: Shifting the culture of a established, science-driven organization to trust and operationalize "black box" AI recommendations requires significant training and stakeholder buy-in across clinical, operational, and commercial teams.